Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.46 |
| ▸ | CASP7 | P55210 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19253219 | 0.95 | ALDH1A1 (0.44) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL28318733 | 0.86 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL27909578 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL22776396 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL28163902 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL11166951 | 0.79 | ALDH1A1 (0.37) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL31554995 | 0.78 | DHFR (0.45) | ALDH1A1HSD17B10CYP3A4HIF1ACASP1 | |
| SCHEMBL30134418 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL3317872 | 0.78 | ALDH1A1 (0.43) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 | |
| SCHEMBL28463321 | 0.77 | ALDH1A1 (0.56) | ALDH1A1HSD17B10CYP3A4HIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730902-B2 | Polyamine transport inhibitors as novel therapeutics | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9620721-B2 | OLEDs having high efficiency and excellent lifetime | GLOBAL OLED TECHNOLOGY LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160151312-A1 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9212131-B2 | Polyamine transport inhibitors as novel therapeutics | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-8795855-B2 | OLEDs having high efficiency and excellent lifetime | GLOBAL OLED TECHNOLOGY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140151676-A1 | OLEDS HAVING HIGH EFFICIENCY AND EXCELLENT LIFETIME | GLOBAL OLED TECHNOLOGY LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120172449-A1 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2012-07-05 | — | — | US | disclosed |
| CN-101960632-B | Tandem OLED device with intermediate connector | GLOBAL OLED TECHNOLOGY LLC | 2012-06-27 | — | — | CN | disclosed |
| CN-101803060-B | High performance broadband OLED device | GLOBAL OLED TECHNOLOGY LLC | 2012-05-23 | — | — | CN | disclosed |
| EP-2109898-B1 | OLEDS HAVING HIGH EFFICIENCY AND EXCELLENT LIFETIME | GLOBAL OLED TECHNOLOGY LLC (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010148390-A2 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| CN-101803060-A | High-performance broadband OLED device | GLOBAL OLED TECHNOLOGY LLC | 2010-08-11 | — | — | CN | disclosed |
| EP-2109898-A1 | OLEDS HAVING HIGH EFFICIENCY AND EXCELLENT LIFETIME | EASTMAN KODAK COMPANY (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1961055-A2 | ELECTROLUMINESCENT DEVICE CONTAINING AN ANTHRACENE DERIVATIVE | EASTMAN KODAK COMPANY (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008094399-A1 | OLEDS HAVING HIGH EFFICIENCY AND EXCELLENT LIFETIME | EASTMAN KODAK COMPANY (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080182129-A1 | OLEDS HAVING HIGH EFFICIENCY AND EXCELLENT LIFETIME | GLOBAL OLED TECHNOLOGY LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2007070251-A2 | ELECTROLUMINESCENT DEVICE CONTAINING AN ANTHRACENE DERIVATIVE | EASTMAN KODAK COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070134512-A1 | Electroluminescent device containing an anthracene derivative | EASTMAN KODAK COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151312-A1 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | SLC19A1, SLC75A1, SLC46A1 | ALDH1A1 2287/4885HSD17B10 3291/4885CYP3A4 3698/4885 |
| US-20120172449-A1 | POLYAMINE TRANSPORT INHIBITORS AS NOVEL THERAPEUTICS | SLC19A1, SLC75A1, SLC46A1 | ALDH1A1 2287/4885HSD17B10 3291/4885CYP3A4 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.